DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers

Information source: University of Michigan Cancer Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Pancreatic Cancer; Biliary Cancer

Intervention: Gemcitabine, 5-FU and Cisplatin (Drug)

Phase: Phase 2

Status: Active, not recruiting

Sponsored by: University of Michigan Cancer Center

Official(s) and/or principal investigator(s):
Mark Zalupski, MD, Principal Investigator, Affiliation: University of Michigan Cancer Center

Summary

Multi-agent chemotherapy has value for patients with advanced pancreatic-biliary cancers leading to responses in a substantial minority and increasing survival. The use of the FOLFIRINOX regimen is limited by its' intensity and toxicity. Previous protocol and clinical experience within the University of Michigan Pancreatic Program leads to an expectation of tolerance and efficacy of the proposed regimen. Advantages of the proposed regimen relative to FOLFIRINOX include: 1. Substitution of gemcitabine for irinotecan. Single agent activity of gemcitabine is at least as good as irinotecan (probably better, especially when delivered by FDR infusion) and gemcitabine is much better tolerated with less diarrhea, nausea/emesis, myelosuppression and alopecia. 2. Deletion of leucovorin infusion and 5FU bolus injection will lessen myelosuppression, mucositis and diarrhea. 3. Substitution of cisplatin for oxaliplatin will reduce cost of therapy and avoid cold aggravated dysesthesia. Presuming evidence of efficacy and confirmation of tolerance with the proposed regimen, the investigators believe this treatment may be more widely applicable to pancreatic-biliary cancer patients, including those with advanced disease as well as being considered for use in locally advanced and neo- and adjuvant settings.

Clinical Details

Official title: A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers

Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Response rate

Secondary outcome: Survival

Detailed description: Gemcitabine combined with 5FU may enhance the activity of 5-FU in vivo. Gemcitabine is an inhibitor of ribonucleotide reductase, an enzyme needed for synthesis of deoxynucleotides, and 5-FU interferes with dTTP synthesis by inhibition of thymidylate synthase (TS). It is likely that concomitant administration of gemcitabine and 5FU results in increased cytotoxicity by reducing intracellular dTTP thru two different mechanisms, thereby inhibiting DNA replication and repair. Platinum compounds lead to cell death by forming DNA adducts and causing double strand breaks. By inhibiting DNA synthesis and repair, both gemcitabine and 5-FU potentiate the activity of cisplatin. These interactions underlie the clinical synergism that has been observed with platinum/5FU and platinum/gemcitabine combinations.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients must have histologic or cytologic diagnosis of pancreatic adenocarcinoma or

biliary tract cancer (intrahepatic or extrahepatic cholangiocarcinoma or gallbladder carcinoma).

- Patients must have clinical/radiologic evidence of metastatic disease.

- Previous systemic therapy for metastatic disease limited to one cytotoxic

chemotherapy regimen not containing cisplatin. Previous therapy for metastatic disease might have included gemcitabine or infusional 5-FU but not both agents.

- ECOG performance status < 1

- Patients must have adequate bone marrow (absolute neutrophil count >1,500/mm3,

platelet count >100,000/mm3) and renal function (serum creatinine < 1. 25 x ULN).

- Patients must have at least one measurable lesion per RECIST criteria.

- Patients must be free of serious concomitant medical disorders incompatible with

study participation including active infection requiring systemic therapy.

- Previous malignancies are permitted provided that they have been treated with

curative intent and patient is without evidence of active systemic disease.

- Patients must be informed of the investigational nature of this study and provide

written informed consent prior to receiving protocol treatment. Exclusion Criteria:

- Patients with pre-existing peripheral neuropathy > grade 2 are ineligible.

- Previous systemic therapy for metastatic disease limited to one cytotoxic

chemotherapy regimen not containing cisplatin.

- Previous therapy for metastatic disease might have included gemcitabine or infusional

5-FU but not both agents.

- Serious concomitant medical disorders incompatible with study participation including

active infection requiring systemic therapy.

Locations and Contacts

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109, United States
Additional Information

Related publications:

Colucci et al., 2002, Louvet et al., 2005, Berlin et al., 2002, Cunningham et al., 2009, Heinemann et al., 2008, Valle et al., 2010

Starting date: July 2011
Last updated: March 2, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017